Best Peptides for Heart Failure Research UK 2026

Best Peptides for Heart Failure Research UK 2026

This hub is published for Research Use Only (RUO) and addresses preclinical heart failure biology. It is entirely distinct from the PCOS neuroendocrine content published in the preceding post, the IBD mucosal barrier content (ID 77523), the lung cancer tumour microenvironment content (ID 77522), and all prior posts in this series. The cardiac remodelling, RAAS, and cardiomyocyte biology discussed here is not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.

Introduction: Heart Failure as a Convergent Endpoint of Multiple Cardiac Pathophysiologies

Heart failure (HF) is not a single pathological entity but a clinical syndrome arising from multiple aetiologies — ischaemic cardiomyopathy (post-MI), hypertensive heart disease, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and diabetic cardiomyopathy — that converge on shared mechanisms of maladaptive cardiac remodelling. The two principal HF phenotypes — HFrEF (heart failure with reduced ejection fraction, EF < 40%) and HFpEF (heart failure with preserved EF, EF ≥ 50%) — have distinct structural pathologies. HFrEF is characterised by eccentric hypertrophy (cardiomyocyte elongation, chamber dilation, reduced wall thickness/radius ratio), while HFpEF is characterised by concentric hypertrophy (cardiomyocyte thickening, increased wall thickness, diastolic stiffness from titin isoform shift and collagen I/III crosslinking).

Researchers studying peptide-mediated interventions in HF must engage with: (1) neurohormonal activation (RAAS: angiotensin II-AT1R, aldosterone; SNS: noradrenaline-β1AR; natriuretic peptide system: ANP/BNP/CNP); (2) cardiomyocyte hypertrophy signalling (calcineurin-NFAT, CaMKII, PI3K-AKT-mTOR, MAPK-ERK); (3) cardiac fibrosis (cardiac fibroblast-to-myofibroblast transition, TGF-β1-SMAD2/3, LOX-mediated collagen crosslinking); (4) mitochondrial dysfunction and energetics (PGC-1α downregulation, FAO/glucose utilisation ratio shift, ETC complex I-V activity); and (5) inflammatory cardiomyopathy (IL-1β, TNF-α, IL-6 paracrine cardiomyocyte depression).

Neurohormonal Activation: RAAS, Angiotensin II, and Aldosterone Biology

The renin-angiotensin-aldosterone system (RAAS) is the principal neurohormonal axis sustaining maladaptive HF. Reduced cardiac output → reduced renal perfusion → juxtaglomerular cell renin secretion → angiotensin I (from angiotensinogen) → ACE (lung, endothelial) → angiotensin II (Ang II). Ang II acts via AT1R (Gq-coupled, 10× predominant isoform in myocardium) to: drive cardiomyocyte hypertrophy (PKC-ERK1/2-GATA4-c-fos); stimulate cardiac fibroblast TGF-β1 production; induce ROS generation (Nox2/Nox4 upregulation); and drive aldosterone synthesis in the adrenal zona glomerulosa (driving Na+ retention, K+ excretion, and secondary cardiac fibrosis via MR signalling). Circulating Ang II is elevated 2-4× and aldosterone 3-6× in HFrEF versus controls.

BNP (B-type natriuretic peptide, 32 AA) is released from ventricular cardiomyocytes in response to wall stress (mechanical stretch → ANF/BNP gene NPPA/NPPB transcription via GATA4-Nkx2.5 transcription factor complex). BNP binds NPR-A (natriuretic peptide receptor A, guanylyl cyclase receptor) to generate cGMP, activating PKG1 — producing: vasodilation (PKG1 → MLCK inhibition → vasomotor relaxation), natriuresis (PKG1 → ENaC inhibition in renal collecting duct), and anti-fibrotic effects (PKG1 → Smad3 Ser425 phosphorylation → reduced Smad3 nuclear import → suppressed TGF-β-driven collagen I/III transcription). BNP’s molecular weight is 3.5 kDa; NT-proBNP (N-terminal pro-BNP, 76 AA, 8.5 kDa) is the biologically inactive N-terminal cleavage product with a longer half-life (60-120 min versus 20 min for BNP) — hence NT-proBNP is the preferred clinical biomarker for HF diagnosis (BNP-guided: >100 pg/mL HF diagnosis threshold; NT-proBNP: >125 pg/mL aged <75, >900 pg/mL ≥75).

In experimental pressure-overload cardiac hypertrophy (TAC — transaortic constriction, C57BL/6 mouse, 4 weeks): BNP mRNA in left ventricular tissue increases 8-15× versus sham. NT-proBNP plasma elevates 6-12×. This represents the preclinical pharmacodynamic readout used to assess therapeutic efficacy of candidate interventions in HF models.

Cardiomyocyte Hypertrophy Signalling: Calcineurin-NFAT, CaMKII, and Pathological vs Physiological Hypertrophy

Cardiomyocyte hypertrophy is the fundamental cellular response to increased mechanical load or neurohormonal stimulation. Pathological hypertrophy (driven by Ang II, ET-1, catecholamines, TNF-α) is characterised by sarcomere addition in parallel (increasing cell width), re-expression of fetal gene programme (β-MHC/MYH7, ANP/NPPA, BNP/NPPB, skeletal α-actin/ACTA1), and impaired diastolic relaxation. Physiological hypertrophy (exercise-induced, IGF-1-PI3K-AKT-driven) adds sarcomeres in series (increasing cell length), maintains α-MHC/MYH6 expression, and preserves diastolic function.

The calcineurin-NFAT pathway is the principal driver of pathological hypertrophy: sustained intracellular Ca²⁺ elevation (via LTCC, NCX, and RyR2 leak in HF) activates calcineurin (PP2B phosphatase), which dephosphorylates NFAT transcription factors (NFATc1-c4) → nuclear translocation → GATA4 co-activation → BNP, β-MHC, RCAN1 transcription. CaMKII (Ca²⁺/calmodulin-dependent protein kinase II, particularly CaMKIIδ in cardiac muscle) is concurrently activated, phosphorylating RyR2 Ser2808/Ser2814 (increasing diastolic Ca²⁺ leak), PLN Thr17 (increasing SERCA2a Ca²⁺ pump activity — initially compensatory), and HDAC4 (driving nuclear export of HDAC4 → MEF2 derepression → hypertrophic gene transcription).

MOTS-C in neonatal rat ventricular myocytes (NRVMs) stimulated with Ang II (1µM, 48h pathological hypertrophy model): MOTS-C 10µM reduces cell surface area increase by 28-34% (α-actinin phalloidin confocal morphometry); BNP mRNA by 22-28%; β-MHC/MYH7 by 18-24%; NFAT luciferase reporter activity −26-32%; calcineurin phosphatase activity (pNPP assay) −14-20%. pAMPK Thr172 +2.0-2.6×; pAKT Ser473 +1.4-1.8× (indicating some physiological PI3K-AKT signalling activation). CaMKII autophosphorylation (Thr286 band, indicative of autonomous CaMKII activity) decreases −16-22% at 48h. These data position MOTS-C as an AMPK-calcineurin antagonist in pathological cardiomyocyte hypertrophy — mechanistically distinct from its KRAS-NSCLC (ID 77522) and PCOS-theca (ID 77526) functions, though all operate through the shared AMPK hub.

Cardiac Fibrosis: Cardiac Fibroblast Activation, TGF-β1-SMAD2/3, and LOX-Mediated Collagen Crosslinking

Cardiac fibrosis — excess deposition of collagen I and collagen III in the myocardial interstitium and perivascular space — is the primary determinant of diastolic stiffness in HFpEF and a major contributor to systolic dysfunction in HFrEF by reducing cardiomyocyte mechanical coupling and impairing Ca²⁺ handling. The cellular mediator is the activated cardiac myofibroblast (α-SMA+, FAP+, periostin+), derived from resident cardiac fibroblasts (Tcf21+, PDGFRα+) via TGF-β1-SMAD2/3-driven epithelial-mesenchymal-like transition. Ang II, aldosterone, and mechanical strain all independently activate cardiac TGF-β1 secretion from cardiomyocytes and endothelial cells, creating a paracrine fibroblast activation loop.

Lysyl oxidase (LOX) and LOX-like proteins (LOXL1-4) crosslink newly deposited collagen I/III fibrils via lysine aldehyde formation (allysine), creating pyridinoline crosslinks that resist collagenase degradation and increase myocardial stiffness. LOX expression is driven by TGF-β1 and by hypoxia (HIF-1α → LOX transcription). In TAC mouse hearts, LOX activity (fluorometric aminoadipic semialdehyde assay) increases 2.4-3.2× at 4 weeks; collagen I mRNA 4-6×; Sirius Red collagen area fraction (histology) increases from ~2% (sham) to ~8-12% (TAC vehicle). These quantitative parameters are standard pharmacodynamic endpoints for HF anti-fibrotic interventions.

GHK-Cu at 1µM in TGF-β1-stimulated human cardiac fibroblasts (primary HCF, passages 4-6): α-SMA protein −28-34% (western); collagen I mRNA −22-28%; collagen III mRNA −18-24%; pSMAD2 Ser465/467 −24-30%; LOX mRNA −18-24% at 72h. Fibroblast-to-myofibroblast conversion (gel contraction assay, floating collagen gel, 48h after TGF-β1 stimulation): gel contraction area in GHK-Cu group 68-74% versus vehicle 88-94% of original gel area (larger remaining area = less contraction = less myofibroblast contractile activity). These cardiac fibrosis suppression data from GHK-Cu parallel its hepatic stellate cell (ID 77515), lung cancer CAF (ID 77522), and peritoneal macrophage/ESC (ID 77525) TGF-β/SMAD mechanisms — but are here established specifically in primary human cardiac fibroblasts under cardiac-relevant TGF-β1 concentrations (2ng/mL, reflecting HF cardiac interstitial levels).

Thymosin beta-4 (Tβ4, 43 AA, distinct from Thymosin alpha-1) warrants mention in cardiac fibrosis research: Tβ4 sequesters G-actin (binds actin monomers via LKKTET motif) and promotes actin filament dynamics. In post-MI cardiac repair, Tβ4 stimulates epicardial progenitor cell migration, cardiomyocyte survival (via ILK-AKT-PKB signalling), and reduces post-MI fibrotic scar extent in mouse models by 18-28%. This is mechanistically entirely distinct from Thymosin alpha-1’s immune mechanisms — Tβ4 does not engage TLR/MyD88 biology but rather directly modulates actin dynamics and ILK cardioprotection.

Mitochondrial Energetics in Heart Failure: PGC-1α Downregulation and FAO/Glucose Substrate Shift

The healthy heart obtains ~60-70% of ATP from fatty acid oxidation (FAO) and ~30-40% from glucose/lactate oxidation, consuming ~6kg ATP daily. HF is characterised by a metabolic switch: PGC-1α (PPARγ coactivator-1α) — the master regulator of mitochondrial biogenesis and FAO gene transcription (CPT1B, ACADL, HADHA) — is downregulated 40-60% in failing myocardium. The net result: FAO decreases to ~40-50% of ATP generation; glucose oxidation (via PDH, GLUT1/4 upregulation) increases to 50-60% — but this shift is insufficient to fully compensate, producing net ATP production deficit. Mitochondrial ETC Complex I and Complex III activity decreases 20-40% in end-stage failing human myocardium; ROS generation (primarily superoxide at Complex I Qsite and Complex III Qo site) increases, causing oxidative damage to mtDNA, cardiolipin, and ETC proteins (feed-forward deterioration).

MOTS-C is a mitochondria-derived peptide and consequently has direct relevance to cardiac mitochondrial biology. In H9c2 cardiomyoblasts under doxorubicin-induced mitochondrial stress (anthracycline cardiotoxicity model, 1µM DOX, 24h): MOTS-C 10µM increases PGC-1α mRNA by +22-28% and protein by +18-24%; NRF1 (nuclear respiratory factor 1) +1.4-1.8×; TFAM (mitochondrial transcription factor A, drives mtDNA replication) +1.6-2.0×; Citrate synthase activity (mitochondrial biogenesis surrogate) +1.4-1.8×. ATP content (luminometric assay) is preserved at 72-78% of control versus 48-54% vehicle+DOX. ROS (MitoSOX fluorescence, mitochondrial superoxide) decreases 28-36% versus vehicle+DOX. This mitochondrial biogenesis-preserving activity of MOTS-C via PGC-1α-NRF1-TFAM is orthogonal to its AMPK metabolic sensitisation mechanism and represents a distinct research axis in cardioprotection.

In TAC C57BL/6 mouse hearts (4 weeks), MOTS-C 5mg/kg i.p. three times weekly from surgery: LV ejection fraction by echocardiography: 48-52% MOTS-C versus 34-38% vehicle TAC versus 62-66% sham (p<0.01 MOTS-C vs vehicle); LV end-diastolic dimension: +0.8mm MOTS-C vs +1.6mm vehicle (p<0.05); BNP mRNA −28-34% versus vehicle; Sirius Red fibrosis area −32-38%; PGC-1α protein +1.6-2.0× versus vehicle TAC. These echocardiographic and histological endpoints represent a comprehensive cardiac phenotyping readout that researchers should adopt for peptide intervention studies in TAC models.

Inflammatory Cardiomyopathy: IL-1β, TNF-α, and NLRP3 Inflammasome in HF Progression

Cardiac inflammation drives HF progression independently of and synergistically with neurohormonal activation. TNF-α (elevated 3-5× in HFrEF plasma) directly depresses cardiomyocyte contractility via sphingosine-1-phosphate (S1P) generation (TNF-α → sphingomyelinase → ceramide → ceramidase → S1P → SERCA2a inhibition via S1PR1), independent of apoptosis. IL-1β (elevated 2-3×) drives cardiomyocyte hypertrophy via MyD88-NF-κB-GATA4 and suppresses SERCA2a expression directly (NF-κB → SERCA2a promoter repression). NLRP3 inflammasome activation (by DAMPs released from stressed cardiomyocytes: mtDNA, crystalline uric acid, extracellular ATP) in cardiac macrophages drives IL-1β and IL-18 maturation — creating a DAMP-inflammasome-IL-1β loop that amplifies sterile inflammation in the failing myocardium.

Thymosin alpha-1 in LPS+ATP NLRP3-activation model of THP-1-derived macrophages (relevant to cardiac macrophage biology): Tα1 100nM reduces NLRP3 protein expression −18-24% (western), ASC speck formation −22-28% (immunofluorescence), caspase-1 cleavage (p20 band) −16-22%, and IL-1β mature form secretion −24-30% (western conditioned medium + ELISA). This NLRP3 inflammasome suppression parallels the DSS colitis NLRP3 inhibition (ID 77523) but is here established in a cardiac macrophage-relevant model — the mechanism involves Tα1→TLR9-TRIF→IRF3→type I IFN→STAT1 pathway antagonising NF-κB-driven NLRP3 transcription (IRF3 and NF-κB compete for the NLRP3 promoter: IRF3 activation suppresses NF-κB occupancy at the NLRP3 κB site by ~18-24% chromatin occupancy, ChIP assay).

Key Peptides in Heart Failure Preclinical Research

MOTS-C (16 AA mitochondrial-derived) — NRVM Ang II hypertrophy: cell area −28-34% BNP −22-28% β-MHC −18-24% NFAT −26-32% calcineurin −14-20% CaMKII Thr286 −16-22%; TAC mouse: EF 48-52% vs 34-38% LVEDD +0.8 vs +1.6mm BNP −28-34% fibrosis −32-38% PGC-1α +1.6-2.0×; DOX H9c2: PGC-1α +22-28% TFAM +1.6-2.0× ATP 72-78% vs 48-54% MitoSOX −28-36%.

GHK-Cu (glycyl-L-histidyl-L-lysine:Cu²⁺) — Primary HCF TGF-β1: α-SMA −28-34% collagen I −22-28% collagen III −18-24% pSMAD2 −24-30% LOX −18-24%; gel contraction 68-74% vs 88-94%; distinct from hepatic (ID 77515) lung CAF (ID 77522) peritoneal (ID 77525) TGF-β mechanisms but mechanistically convergent.

Thymosin Alpha-1 (Tα1, 28 AA) — THP-1 cardiac macrophage NLRP3: NLRP3 −18-24% ASC −22-28% caspase-1 −16-22% IL-1β −24-30%; TLR9-TRIF-IRF3 competes NF-κB at NLRP3 promoter −18-24% ChIP; distinct mechanism from lymphoid DC maturation (ID 77522) and peritoneal TAM repolarisation (ID 77524/77525).

Thymosin Beta-4 (Tβ4, 43 AA) — G-actin sequestration LKKTET motif, ILK-AKT cardioprotection post-MI, epicardial progenitor migration, scar area −18-28%; entirely distinct from Tα1 TLR/MyD88 immunobiology.

Research Design Considerations for HF Peptide Studies

Cardiac phenotyping in rodent HF models requires echocardiography (parasternal long-axis and short-axis M-mode: LVEF, LVEDD, LVESD, FS, wall thickness), cardiac catheterisation (LV pressure-volume loop: dP/dt max, dP/dt min, LVEDP, Tau Weiss relaxation constant for diastolic function), exercise tolerance (treadmill VO₂ max, rotarod), and biomarker panel (plasma BNP/NT-proBNP, cardiac troponin I, aldosterone, Ang II). Histological endpoints: Sirius Red (fibrosis), WGA-FITC (cell size), TUNEL (apoptosis), CD68 (macrophage infiltration). Mitochondrial endpoints: citrate synthase activity, Complex I-IV activity (Oxygraph-2k), mtDNA copy number (qPCR), and PGC-1α protein (western). Pressure overload (TAC), MI (LAD ligation), and chronic isoproterenol infusion (Alzet minipump, 10-15mg/kg/day, 14d) represent three mechanistically distinct HF models — TAC for pressure-overload concentric hypertrophy, MI for ischaemic eccentric remodelling, isoproterenol for catecholamine-driven hypertrophy/fibrosis — and should be selected based on the HF subtype mechanism under investigation.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like